Additionally, eotaxin-2 and -3 concentrations were significantly higher in asthma patients treated with 200 mg of benralizumab (antibody against the alpha-chain of the interleukin-5 receptor) after 84 days of treatment [58]. Here, CCL24 is linked to asthma.